HKMPF Stock Analysis
HK
Avoid
Based on Eyestock quantitative analysis, HKMPF`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. The company also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.